安罗替尼联合化疗治疗乳腺恶性叶状肿瘤1例报道并文献复习  

Anlotinib combined with chemotherapy in the treatment of malignant phyllodes tumors of the breast:a case report and literature review

作　　者：安天棋 宗红[1] 王正洋 刘敏 赵瑞华[1] An Tianqi;Zong Hong;Wang Zhengyang;Liu Min;Zhao Ruihua(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Pathology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Medical Science,Berry Oncology Corporation Co.,Ltd.,Fujian Province,Fuzhou 350200,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450000 [2]郑州大学第一附属医院病理科,郑州450000 [3]福建和瑞基因科技有限公司医学部,福州350200

出　　处：《中国医药》2023年第4期593-595,共3页China Medicine

基　　金：河南省科技发展计划(202300410383)。

摘　　要：乳腺叶状肿瘤(PT)是一种罕见的纤维上皮性肿瘤,在组织学上可分为良性、交界性及恶性3种。恶性PT发病率低,预后差。目前临床上对晚期恶性PT的治疗暂无统一标准可供参考。本文报道1例恶性程度高、术后多次复发并远处转移的恶性PT患者,患者经一线治疗后病情迅速进展,而接受安罗替尼联合化疗后却获得长时间的病情缓解,疗效显著,提示安罗替尼联合化疗可能成为恶性PT治疗的新选择。Phyllodes tumors of the breast(PT)is a rare fibroepithelial tumor.It can be histologically classified as benign,borderline and malignant.Malignant PT has low morbidity and poor prognosis.At present,there is no uniform standard for the treatment of advanced malignant PT clinically.This paper reports a case of malignant PT patient with high malignancy,multiple postoperative relapses and distant metastases,who progressed rapidly following first-line treatment,but achieved long-term remission with remarkable efficacy after receiving anlotinib combined with chemotherapy.It is suggested that anlotinib combined with chemotherapy may be a new therapeutic option for malignant PT.

关 键 词：乳腺恶性叶状肿瘤 安罗替尼 酪氨酸激酶抑制剂 联合治疗 

分 类 号：R737.9[医药卫生—肿瘤]